M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout Pharmaceutical TechnologyJ J strikes its deal with Sail as the in vivo CAR-T space becomes increasingly crowded, with several big pharma players betting on the class.OncologyRead full story pharminent July 31, 2026 (Last updated: August 3, 2026) Pharmaceutical Technology J J strikes its deal with Sail as the in vivo CAR-T space becomes increasingly crowded, with several big pharma players betting on the class. Oncology Read full story Post navigation Previous: Amgen’s Repatha Wins Positive CHMP Opinion for Preventing First Heart Attacks and StrokesNext: Outlook Therapeutics Secures FDA Approval for LYTENAVA Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026